
The most common question patients ask when they start a new treatment after a new diagnosis is "what will this do to me?" explained Sally Okun, RN, MMHS, vice president, Policy and Ethics, PatientsLikeMe.

The most common question patients ask when they start a new treatment after a new diagnosis is "what will this do to me?" explained Sally Okun, RN, MMHS, vice president, Policy and Ethics, PatientsLikeMe.

Different value-based payment approaches are evolving for different sorts of conditions, different sorts of financial circumstances, and other factors, explained Clifford Goodman, PhD, senior vice president and director, Center for Comparative Effectiveness Research, The Lewin Group.

There are small subgroups within each tumor type and within each molecular type, and someday, we might be able to actually pair the 2 to give patients a little bit more personalization and precision to their treatments, said Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology.

Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center, discusses the shift toward interoperability among electronic health record systems and efforts needed to accelerate this shift.

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, discusses challenges associated with conducting precision medicine trials in the community setting.

Rear Admiral Wanda Barfield, MD, MPH, director of the Division of Reproductive Health for the CDC, discusses the initiatives that have played a role in the decrease of teen pregnancy in the United States.

The purpose of Project Baseline is to map human health so we can convert from a reactive healthcare system to a proactive healthcare system, explained Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine

It’s been years since a large portion of colon cancer patients have seen any innovations in treatment. However, there are dietary and physical behavioral changes individuals can make that positively impact colon cancer survival said Leonard Saltz, MD, executive director of Clinical Value and Sustainability, head of Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center.

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses different prevention methods in ovarian cancer.

We need to collaborate and test these innovations in controlled circumstances so that we can evaluate their effect and understand what needs to be iterated to continue to improve them, explained Harlan Krumholz, MD, SM, the Harold H. Hines Jr professor, Medicine and Epidemiology and Public Health, Yale School of Medicine, and director, Center for Outcomes Research and Evaluation, Yale-New Haven Hospital.

There are a lot of new and exciting agents that are being explored for metastatic HER2-positive disease, explained Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute.

Jamie Bakkum-Gamez, MD, associate professor of obstetrics and gynecology and Gynecologic oncologist at Mayo Clinic, discusses her research on developing an early detection test for endometrial cancer.

Not all health data is collected in a similar manner, so analyzing such data can be challenging for researchers, explained Ejim E. Mark, MD, MPH, MBA, CEO and founder of Access Healthcare Foundation.

The unique composition and massive size of California’s population means that health plans and systems in the state have had to explore new ways to improve the delivery of healthcare for those with complex health and social needs, according to panelists at the AHIP Institute & Expo 2018.

Immune therapies, or check point inhibitors, have been very successful in a subset of patient with multiple different types of malignancies and has changed their trajectory tremendously, explained Victoria Villaflor, MD, associate professor of Medicine, hematology and oncology, Northwestern University.

Sally Okun, RN, MMHS, vice president, Policy and Ethics, PatientsLikeMe, discusses findings from PatientsLikeMe's research on what patients define as good care.

Rear Admiral Wanda Barfield, MD, MPH, director of the Division of Reproductive Health for the CDC, discusses how the CDC is working to counteract perinatal morbidity and mortality in the United States.

People are getting better at handling data in their electronic health records (EHRs), but there is a lot and there should be a way to categorize how the data should be used, said Pamela Tobias, MS, RHIA, CHDA, administrator of oncology services at Lehigh Valley Health Network.

Haywood Brown, MD, immediate past president of the American College of Obstetricians and Gynecology, discusses the Alliance for Innovation in Maternal health (AIM) program which is designed to decrease the top-leading causes of maternal morbidity and mortality.

After natural disasters like wildfires in California and hurricanes in Puerto Rico, leaders from an integrated healthcare system and a health plan spoke at the AHIP Institute & Expo to share their first-hand lessons on how businesses can continue their operations when disaster strikes.

A day after making headlines as he was announced CEO of the new joint healthcare company formed by Amazon, Berkshire Hathaway, and JPMorgan Chase, Atul Gawande, MD, took the stage at the America's Health Insurance Plans Institute & Expo to deliver a talk on the importance of thoughtful care, particularly at the end of life, and how it can be incorporated into a better healthcare system.

Healthcare could learn some lessons on preventing burnout from air traffic control, which is a high-stress workspace that has a very low burnout rate, said James Grayson, administrative chief of staff at West Cancer Center.

At the America's Health Insurance Plans Institute & Expo, a presentation focused on how artificial intelligence (AI) solutions can help payers deliver the seamless experience that consumers have come to expect.

At a session during the America's Health Insurance Plans Institute & Expo, panelists representing insurers discussed the actions taken by their organizations as they strive toward health equity.

Next-generation sequencings tests are just starting to change the landscape for cancer patients, explained Peter Paul Yu, MD, FASCO, FACP, physician-in-chief, Hartford HealthCare Cancer Center.

At the America’s Health Insurance Plans Institute and Expo, held in San Diego, California, June 20-22, Ezekiel J. Emanuel, MD, of the University of Pennsylvania’s Wharton School and School of Medicine, presented his “prescription for success” for improving healthcare in United States.

Mary Norine Walsh, MD, immediate past president of the American College of Cardiology, discusses the symptoms of peripartum cardiomyopathy, and who is at the highest risk for developing it.

Dennis P. Scanlon, PhD, professor, Health Policy and Administration, and director, Center for Health Care and Policy Research, Pennsylvania State University, discusses how well the United States health system scales successful pilots in delivering value-based care across the country.

Adrian F. Hernandez, MD, MHS, vice dean, clinical research, Duke University School of Medicine discusses how technology can be used to improve the way we gather and use real-world evidence, the promise that real-world evidence holds, and how he thinks real-world evidence will be used in the coming years.

John Schorge, MD, associate editor of The Green Journal, and Gynecologic Oncologist at Tufts Medical Center, discusses his research on the disparities in the care of endometrial cancer.

259 Prospect Plains Rd, Bldg H
 Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
